Navigation Links
No Lymphoma Risk From Rheumatoid Arthritis Drugs

There has been an increasing fear regarding the elevated risk of lymphoma associated with rheumatoid arthritis treatment// A new study by Swedish researchers has found that such treatments may not confer an increased susceptibility to cancer, the results of which can be seen in the latest issue of Arthritis & Rheumatism journal.

The risk of cancer has been found to increase with worsening of the chronic inflammatory process. In other words, a cause-effect relationship has been established with the disease severity and cancer risk. Infact the drugs given for symptomatic treatment of rheumatoid arthritis, which, prevent further progress of the inflammation may actually reduce the cancer risk.

Rheumatoid arthritis is a progressive disease, characterized by inflammation of joints resulting in pain, joint damage, immobility and finally disability. Nearly 2 million Americans have been diagnosed with the chronic disease, according to estimates by the Arthritis Foundation. Non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biologic response modifiers (new generation drugs) and analgesics are currently being given for treatment.

The researchers studied data obtained from nearly 75,000 rheumatoid arthritis patients. Amongst these, 378 patients developed lymphoma during the course of treatment. The data obtained was compared with that obtained from 378 healthy controls. The severity of the disease (low, medium, high), the duration of the disease, the level of inflammation or tenderness in the joints was some of the factors taken into consideration.

The results of the analysis established that individuals with high activity (severe disease) had a 70-fold increased risk of developing lymphoma. The severity of involvement of knees, hands and feet within the first year of diagnosis was also found to confer an increased risk. The lymphoma risk was much lower (8 fold) in those who ha d medium disease activity.

Furthermore, no increased risk of lymphoma was found in those who were given anti-rheumatic drugs (DMARDS), including the drug methotrexate (anti-cancer drug). No increased risk could also be documented with use of steroids or NSAIDs. Surprisingly, the incidence of lymphoma in those who were given corticosteriods injections was the lowest, probably highlighting its role in cancer prevention.

The results of the present study highlight the need for early identification and aggressive treatment to prevent worsening of the disease. To conclude, the more severe the disease, the higher is the cancer risk. The provision of appropriate anti-rheumatic treatment can decrease the disease related complications.


'"/>




Related medicine news :

1. Lymphomas Link to Hepatitis C
2. New Guidelines For Assessing Lymphoma Treatment
3. A Novel Treatment for KSHV-infected Lymphomas
4. New treatment for Rheumatoid Arthritis
5. New Rheumatoid Arthritis Treatment
6. New Rheumatoid Arthritis Treatment
7. Consumption Of Red Meat Found To Double The Risk of Rheumatoid Arthritis
8. The Link Between Rheumatoid Arthritis And Heart Failure
9. Smoking during pregnancy increases risk of Rheumatoid Arthritis.
10. Good News For Those Of You Suffering From Rheumatoid Arthritis
11. Mineral Oil exposure increases risk of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines ... despite scientific studies, the Center for Disease Control ( CDC ) and Infectious Diseases ... Kenneth B. Liegner, M.D. has compiled into a single volume a compelling argument that ...
(Date:2/27/2017)... Francisco, CA (PRWEB) , ... February 27, 2017 ... ... clinic serving San Francisco and environs, is proud to announce an upgrade to ... information on the upgraded Yelp page on topics as diverse as Platelet Rich ...
(Date:2/26/2017)... ... 2017 , ... This is an extension of airmid’s scope ... ISO/IEC 17025:2005 INAB accredited for Der p 1 (house dust mite allergen) & ... standard that sets out requirements for the technical competence of testing and calibration ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... technology standard in staffing, scheduling, and reporting for healthcare organizations. This comprehensive ... throughout the entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource ...
(Date:2/25/2017)... ... , ... FCPX users now have the ability to sharpen a desired color ... users have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical sharpening, ... users can visually see the color range effected with ease all within Final ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 23, 2017 Report analyzes the worldwide markets for ... analytics for the US, Canada , ... Asia-Pacific , Latin America , ... for the period 2015 through 2022. Also, a six-year historic ... are derived from primary and secondary research. Company profiles are ...
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... -- This report analyzes the worldwide markets for Chiral Technology ... Products: Intermediates, Analytical, and Others. The End Use markets ... The report provides separate comprehensive analytics for the US, ... , and Rest of World. Annual estimates and forecasts ... a six-year historic analysis is provided for these markets. ...
Breaking Medicine Technology: